Seelos Therapeutics Doses First Patient in an Open Label Basket Study of SLS-005 in Amyotrophic Lateral Sclerosis in Australia and Provides an Enrollment Update of its Study on the HEALEY ALS Platform

By
Bob
-
0
255
Seelos Therapeutics, Inc. announced dosing of the first patient in an open-label basket study of SLS-005 for the treatment of patients with amyotrophic lateral sclerosis in Australia.
[Seelos Therapeutics, Inc.]
Press Release